Featured Slider

The first team of board members is going to retire after the Lisbon congress and the incoming president, Franz Fazekas from Graz, Austria, will take over. He is an outstanding scientist in the field of Stroke and Multiple Sclerosis and has done a marvellous job for our Society during the past 4 years. His many qualities as an Austrian Cosmopolitan are a guarantee for an integrative presidency for the next years of further development of this young Society. It is my privilege to thank him and the outgoing board for an excellent collaboration.

As every year, spring time is high season for preparing for the annual congress - this year the 4th congress of the European Academy of Neurology in Lisbon. It is the annual main event of our Society and we expect around 6000 participants in this special and historically attractive Portuguese capital. The congress has continuously adapted its profile and one of the main goals of our Society is to continuously develop new formats which satisfy the requests of modern neurology and its drivers, the European Neurologists. Our program committee under the leadership of Prof. Boon has excellently realized this request with many new innovations.

For May 2018, we have selected: Kappos L, Bar-Or A, Cree BAC, et al., for the EXPAND Clinical Investigators. Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomized, phase 3 study. Lancet Neurol 2018;391:1263-1273. Secondary progressive multiple sclerosis (SPMS) is characterized by a previous history of relapsing remitting MS (RRMS) and the continuous progression of disability over the years typically without relapses.

Portugal is a country with a 900-year history: many remnants of past colonization by Celtics, Romans, and Arabians are still present. Unquestionably, the greater contribution of Portugal to the humanity have been the overseas navigations around the world, namely the discovery of the maritime way to India, the discovery of Brazil and of several Atlantic islands.

Education is one of the key elements of the activities of the European Academy of Neurology. While the congress is well known to most of our members and European Neurologists the activities outside the congress are much less known. EAN has a special committee working on education[1] with Prof. Hannah Cock as the chair and the teaching course subcommittee under the leadership of Prof. Claudia Sommer. They are charged to develop an educational program including education for neurologists in training and advanced courses with the emphasis on training for the general neurologist. While the field of Neurology is getting increasingly broader it is of paramount importance to set a common ground for all neurologists which our education committee has carefully developed. For the congress educational programme, a five-year curriculum of the educational content covering all relevant topics has been developed over the past 3 years and parts of this plan are also applied to the educational activities outside the congress.

For April 2018, we have selected: Whelan CD, Altmann A, Botia JA, et al., for the ENIGMA-Epilepsy Working Group. Structural brain abnormalities in the common epilepsies assessed in a worldwide ENIGMA study. Brain 2018;141:391-408. Epilepsy affects 0.6-1.5% of the population worldwide with one-third of patients being resistant to antiepileptic treatment. Nowadays epilepsy is considered a network disorder in which several structural changes are involved.

Slovakia, officially the Slovak Republic, is a country in Central Europe. The total area of the Slovak territory is 49 036 km2 and is mostly mountainous. The population is over 5 million. The capital and largest city is Bratislava. However, the Slovak Republic is a young state (established on January 1st, 1993, by the split of Czechoslovakia), indeed it is an old country with rich historical heritage.

The Republic of Lithuania is a state in northern-eastern Europe occupying 65.300 km2 area with Vilnius city as capital and a population of 2.979.000 inhabitants. Neighbors of Lithuania are Latvia, Belarus, Poland, and Russia. It is a parliamentary democracy, with… Continue Reading

by Elena Moro For March 2018, we have selected: Honig LS, Vellas B, Woodward M, et al. Trial of solanezumab for mild dementia due to Alzheimer’s disease. N Engl J Med 2018;378:321-330. Alzheimer’s disease (AD) pathology can be related to either excessive production or reduced elimination of beta amyloid (Aβ), which eventually results in oligomers, fibrils, and neuritic Aβ plaques.

Prof. Corino de Andrade graduated at Lisbon Medical School, Hospital of St Martha, in 1929. He began his practice at the main hospital in Lisbon (Hospital S. José) and kept visiting his Alma Mater with a serious commitment to practice neurology at the department of Egas Moniz, the only one in Portugal. This passion was soon rewarded with the residency in neurology.

Neurological diseases have a very different frequency. Neurological practice and brain research need to have this in mind. The global burden of disease study has shown that neurologic diseases are the leading cause group of disability-adjusted life years (DALYs) of all medical disease groups in 2015 with 10.2% of global DALYs. Table 1 shows the age-standardized rates of DALYs, deaths and the prevalence of the different neurologic diseases.1 In this schematic rare neurological diseases are mostly covered within the category ‘other neurological diseases’. The prevalence cannot be estimated based on the available data. However, the number of existing rare neurological diseases is very large. The current website of the NIH lists 1244 neurologic rare diseases which is the largest number among all rare disease groups and covers approximately 60% of rare diseases.2 These more than 1200 diseases produce more than 0.9% of the neurological DALYs world-wide which seems at first glance to be relatively small.

For February 2018, we have selected: Feneberg E, Oeckl P, Steinacker P, et al. Multicenter evaluation of neurofilaments in early symptom onset amyotrophic lateral sclerosis. Neurology 2018;90:e22-30. doi:10.1212/WNL.0000000000004761. Amyotrophic lateral sclerosis (ALS) is a devastating neurological disorder affecting motor neurons. The course of the disease is progressive with life span of 3 to 5 years from the onset of the symptoms.

Kyrgyzstan is a Central Asia country of incredible natural beauty and proud nomadic traditions, landlocked and extremely mountainous with almost 90% of its territory being 1500 m above sea level. Its capital and largest city is Bishkek.

by Prof. Victor Oliveira, University of Lisboa, Portugal – Member of the Local Organising Committee for the 4th EAN Congress in Lisbon, Portugal Egas Moniz (1874-1955) was a Portuguese neurologist whose name is associated to the invention of angiography and… Continue Reading